The New York Times reports:
The coronavirus vaccine developed by AstraZeneca and the University of Oxford provided strong protection against Covid-19 in a large clinical trial in the United States, completely preventing the worst outcomes from the disease while causing no serious side effects, according to results announced on Monday.
The findings, announced in a news release from AstraZeneca, may help shore up global confidence in the vaccine, which was shaken this month when more than a dozen countries, mostly in Europe, temporarily suspended the use of the shot over concerns about possible rare side effects.
But the fresh data may not make much difference in the United States, where the vaccine is not yet authorized and may not be needed.
Read the full article.
AstraZeneca’s Covid-19 vaccine showed 79% efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization in a new, US-based clinical trial, the company said.
The trial identified no safety concerns, AstraZeneca said. https://t.co/qTKaDRjwMO
— CNN (@CNN) March 22, 2021